Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Elicio Therapeutics (ELTX) Return on Capital Employed (2021 - 2026)

Elicio Therapeutics filings provide 3 years of Return on Capital Employed readings, the most recent being 185.1% for Q4 2023.

  • On a quarterly basis, Return on Capital Employed fell 9271.0% to 185.1% in Q4 2023 year-over-year; TTM through Dec 2023 was 185.1%, a 9271.0% decrease, with the full-year FY2023 number at 235.94%, down 19092.0% from a year prior.
  • Return on Capital Employed hit 185.1% in Q4 2023 for Elicio Therapeutics, down from 141.62% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 20.48% in Q3 2022 to a low of 185.1% in Q4 2023.
  • Median Return on Capital Employed over the past 3 years was 75.04% (2021), compared with a mean of 77.91%.
  • Biggest five-year swings in Return on Capital Employed: surged 4751bps in 2022 and later tumbled -12114bps in 2023.
  • Elicio Therapeutics' Return on Capital Employed stood at 42.76% in 2021, then tumbled by -116bps to 92.39% in 2022, then tumbled by -100bps to 185.1% in 2023.
  • The last three reported values for Return on Capital Employed were 185.1% (Q4 2023), 141.62% (Q3 2023), and 85.1% (Q2 2023) per Business Quant data.